Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

Halling, Anne-Sofie, Loft, Nikolai, Silverberg, Jonathan I., Guttman-Yassky, Emma, Thyssen, Jacob P.·2021·Journal of the American Academy of Dermatology

Abstract

BACKGROUND Dupilumab, the first biological drug to be approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults has shown good efficacy and safety in clinical trials. OBJECTIVE To evaluate real-world data on the efficacy and safety of dupilumab in AD. METHODS Pubmed and Embase were searched for observational studies with data on efficacy, drug survival and safety of dupilumab for the treatment of AD. Primary outcomes were mean percentage change in Eczema Area and Severity Index (EASI), and proportion of AD patients achieving 50%, 75% and 90% improvement in EASI (EASI-50, 75 and 90) following dupilumab therapy. RESULTS 22 unique studies encompassing 3,303 AD patients were included. After 16 weeks of dupilumab therapy, the pooled proportion of patients achieving EASI-50, EASI-75 and EASI-90 was 85.1%, 59.8% and 26.8%, and the weighted mean reduction in EASI was 69.6%. Conjunctivitis was the most common adverse event, reported in a pooled proportion of 26.1%. LIMITATIONS Limited data in terms of size and follow-up time was available. CONCLUSION Real-world data show that dupilumab is a successful and well-tolerated therapy for AD, but ocular adverse events commonly occur. Registries are needed to monitor for adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2020.08.051

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 288

Metadata

Authors
Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2021-01
Volume
84
Issue
1
Pages
139-147
ISSN
0190-9622 (ISSN-L)
OpenAlex
W3063829097
Cited by
288
References
40
FWCI
7.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/j.jaad.2020.08.051
The paper
Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P. (2021). Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.08.051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.